pyrotinib,docetaxel,trastuzumab
sanofi,aventis,roche,jiangsu hengrui pharmaceuticals
['breast', 'docetaxel', 'pyrotinib', 'trastuzumab,(-trastuzumab deruxtecan),(-trastuzumab-deruxtecan)']
dr binghe xu: randomized phase iii trial found that pyrotinib + trastuzumab + docetaxel significantly prolonged progression free survival in patients with her2-positive metastatic breast cancer compared with placebo+ trastuzumab + docetaxel. #esmo2022
Flagship #OpenAccess medical journal from @BioMedCentral. Publishes research articles & reviews in all areas of research & practice in #medicine & #globalhealth